GABRG2
Gamma-aminobutyric acid receptor subunit gamma-2
As of the edition of 20 October 2026, GABRG2 (gamma-aminobutyric acid receptor subunit gamma-2, UniProt P18507) has 27 drugs tested at it and 10 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P18507
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 84
- Disease areas
- Nervous system; Mental health; Cancer; Lungs and airways; Infections; Urinary and reproductive; Digestive system; Immune system
- Registered trials of its drugs
- 1,324
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 23 |
| Went quiet | 2 |
| Stopped | 2 |
| Total | 27 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Midazolam | Marketed | Phase 4 | none listed |
| Remimazolam | Marketed | Phase 4 | none listed |
| Zolpidem | Marketed | Phase 4 | none listed |
| Lorazepam | Marketed | Phase 4 | none listed |
| Alprazolam | Marketed | Phase 4 | none listed |
| Eszopiclone | Marketed | Phase 4 | none listed |
| Diazepam | Marketed | Phase 4 | none listed |
| Clonazepam | Marketed | Phase 4 | none listed |
| Flumazenil | Marketed | Phase 4 | none listed |
| Clobazam | Marketed | Phase 4 | none listed |
| Padsevonil | Stopped | Phase 3 | none listed |
| Zaleplon | Marketed | Phase 4 | none listed |
12 of 27 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Undetermined | 9 |
| Total on the list | 10 |
| Company | Route |
|---|---|
| Pfizer | Route B |
The other 9 companies at GABRG2
In the product10 companies in all; 9 are not named here, and no score is.
See the 10 companies at GABRG2, ranked, with the facts behind eachRequest access. Nothing is shown until you do.